iRGD-engineered exosomes mediate siMYC delivery for effective tumor suppression in triple-negative breast cancer

作者：Hui Li, Weiguang Yuan, Jialin Liu, Yingjie Wang, Fang Fang, Yuanyuan Yu, Jianxun Hou, Mengru Jin, Siwei Li, Siyu Liu, Yajie Gong, Yijun Chu, Xingda Zhang, Xingda Zhang, Shilu Zhao, Wenhui Hao, Xuquan Qin, Qinchen Fan, Xi Chen, Youxue Zhang, Da Pang, Xianyu Zhang, Xianyu Zhang · 发表于：Nanoscale · 年份：2025 · DOI：10.1039/d5nr04841a · 被引用次数：2 · 研究领域：Extracellular vesicles in disease、Nanoplatforms for cancer theranostics、RNA Interference and Gene Delivery

, iRGD-Exos-siMYC exhibited superior tumor-targeting capability, effectively inhibiting tumor growth and significantly downregulating MYC expression. Moreover, biosafety evaluations confirmed that iRGD-Exos-siMYC possesses good biosafety. This study demonstrated that iRGD-modified exosomes can effectively deliver siMYC to TNBC cells, enhancing gene silencing and antitumor efficacy. The targeted exosomal drug delivery system showed high tumor selectivity and minimal systemic toxicity. These findings provide new insights into exosome-based gene therapy and highlight the value of iRGD-Exos-siMYC as a novel treatment strategy for TNBC.